Navigation Links
FDA Approves Duramed's LoSEASONIQUE(R) Oral Contraceptive
Date:10/27/2008

nvironment in the markets where we operate; our exposure to product liability and other lawsuits and contingencies; the increasing cost of insurance and the availability of product liability insurance coverage; our timely and successful completion of strategic initiatives, including integrating companies (such as PLIVA d.d.) and products we acquire; fluctuations in operating results, including the effects on such results from spending for research and development, sales and marketing activities and patent challenge activities; the inherent uncertainty associated with financial projections; our expansion into international markets through our PLIVA acquisition, and the resulting currency, governmental, regulatory and other risks involved with international operations; our ability to service our significantly increased debt obligations as a result of the PLIVA acquisition; changes in generally accepted accounting principles; the reactions of the Company's customers and suppliers to the merger; and diversion of management time on merger-related issues. These and other applicable risks, cautionary statements and factors that could cause actual results to differ from the Company's forward-looking statements are included in the Company's filings with the U.S. Securities and Exchange Commission ("SEC"), specifically as described in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2007. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.

Important Legal Information

In connection with the proposed merger, the Company will prepare a proxy statement to be filed with the SEC. When completed, a definitive proxy statement and a form of proxy will be mailed to the stockholders of the Company. Before making any voting decision, the Company's stockholders are urged to read the proxy statement regarding the merger carefully and in its entirety because it wil
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
2. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
3. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
4. FDA Approves Fougeras Clotrimazole Cream USP 1%
5. FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
6. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
7. Signalife Board Approves Merger
8. FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
9. FDA Approves Abbotts XIENCE(TM) V Drug Eluting Stent
10. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
11. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Tenn. , May 4, 2015   ... developed a significantly better computer tool for finding ... many cancers but were difficult to identify with ... scientific journal Nature Methods . ... for Copy Number Segmentation by Regression Tree in ...
(Date:5/4/2015)... May 4, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on Form 20-F for the fiscal year ended December ... ("SEC"). The annual report on Form 20-F contains information ... in the area of cancer immune checkpoints. This project ... high specificity and binding in targeting certain identified immune ...
(Date:5/4/2015)... May 4, 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), ... the appointment of Dr. Roger J Garceau, to ... biotech companies in matters including corporate development and ... and adds significant regulatory expertise as Fluorinov transitions ... brings 30 years of pharmaceutical development experience to ...
(Date:5/4/2015)... May 4, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... an independent team of researchers from ... B4 (TB4) plays an important role in accelerating ... in an experimental mouse model, by promoting blood ... damaged dermal tissue.  The research found that the ...
Breaking Biology Technology:Scientists dramatically improve method for finding common genetic alterations in tumors 2Scientists dramatically improve method for finding common genetic alterations in tumors 3Scientists dramatically improve method for finding common genetic alterations in tumors 4Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 2Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 3
... The University of Nottingham have made a major breakthrough that ... the first time that 3-D molecular structures can be built ... step forward towards the development of new nano devices such ... In a paper published in the prestigious journal ...
... search for the next generation of semiconductors. Researchers ... National Laboratory (Berkeley Lab) and the University of ... of the semiconductor indium arsenide onto a silicon ... electronic properties. A member of the IIIV family ...
... first isolated in 2004 with the help of Scotch ... discover its potential applications. A single layer of carbon ... to flexible displays, graphene is strong, light, transparent, and ... we do with this new material? As researchers across ...
Cached Biology Technology:World-first to provide building blocks for new nano devices 2Ultrathin alternative to silicon for future electronics 2Ultrathin alternative to silicon for future electronics 3Doctoral candidate publishes on graphene's potential with NSF support 2Doctoral candidate publishes on graphene's potential with NSF support 3Doctoral candidate publishes on graphene's potential with NSF support 4
(Date:3/31/2015)... --  Guidepoint , a leading global research services firm, ... TRACKER, part of the Guidepoint TRACKER suite ... device and therapeutics markets. The Post-Surgical Pain Management TRACKER ... share, and adoption rates across three major modalities used ... The Post-Surgical Pain Management TRACKER will provide length ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition ... Report" report to their offering. This report analyzes ... by the following Segments: Face Biometrics, and Voice Biometrics. The report ... , Japan , Europe , ... & Africa , and Latin America ...
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs , ... company, today announced that the Company will demonstrate multiple ... enterprise and consumers at Connect:ID on March 23 through ... HOYOS Labs will highlight the IEEE Biometric Open Protocol ... ; and enterprise access control system. BOPS was invented ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... April 23, 2012 /PRNewswire-iReach/  -- Global Information Inc. ... discounted registration for three important Boston healthcare conferences: ... Pioneers from across the rapidly maturing kinase inhibitors field ... lies ahead at the Next-Gen Kinase Inhibitors Conference ...
... is a disorder in which there are recurring episodes of upper ... estimated to affect 1 in 5 adults in America. The serious ... found that middle-age and older men with even mild levels of ... While a link between OSA and stroke is clear, OSA,s effect ...
... of breast milk are well known, but why breastfeeding protects ... study in the Journal of Human Lactation (published ... ligand (TRAIL) in human milk, which might be one source ... samples of colostrum, the first milk available to newborns, and ...
Cached Biology News:Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 2Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27 3Obstructive sleep apnea's damage evident after 1 month 2